Oropharynx Clinical Trials

1 recruiting

Oropharynx Trials at a Glance

43 actively recruiting trials for oropharynx are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 19 trials, with the heaviest enrollment activity in New York, Paris, and Montreal. Lead sponsors running oropharynx studies include Centre hospitalier de l'Université de Montréal (CHUM), Christian Hinrichs, and Memorial Sloan Kettering Cancer Center.

Browse oropharynx trials by phase

Treatments under study

About Oropharynx Clinical Trials

Looking for clinical trials for Oropharynx? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oropharynx trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oropharynx clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

Head and Neck Squamous Cell CarcinomaCarcinoma, Squamous CellOropharyngeal Squamous Cell Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center220 enrolled3 locationsNCT04564989
Recruiting
Phase 2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting
Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Head and Neck CancerOropharynx CancerHypopharynx Cancer+3 more
Mayo Clinic25 enrolled1 locationNCT06997068
Recruiting
Phase 3

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Oropharynx CancerLarynx CancerHypopharynx Cancer+1 more
Centre Leon Berard460 enrolled8 locationsNCT06706401
Recruiting
Phase 2

The Minimalist Trial-2

HPV-Related Oropharynx Squamous Cell Carcinoma
Washington University School of Medicine142 enrolled1 locationNCT06702033
Recruiting
Phase 2

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

HPV-Related MalignancyHPV-Related CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
Memorial Sloan Kettering Cancer Center30 enrolled8 locationsNCT05307939
Recruiting
Not Applicable

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

Oropharynx Cancer
Georgetown University30 enrolled1 locationNCT06554158
Recruiting

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

Squamous Cell Carcinoma of OropharynxOral Cavity Squamous Cell CarcinomaLarynx Squamous Cell Carcinoma+1 more
University of Erlangen-Nürnberg Medical School250 enrolled1 locationNCT06947668
Recruiting
Phase 2Phase 3

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the LarynxSquamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the Oral Cavity+1 more
University of Erlangen-Nürnberg Medical School508 enrolled1 locationNCT06030440
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Not Applicable

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

Oropharynx Cancer
Duke University120 enrolled2 locationsNCT04667585
Recruiting
Phase 2

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Squamous Cell Carcinoma of Head and NeckOral Cavity CancerNasal Cavity Cancer+9 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07063212
Recruiting

Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action

Newly Diagnosed Cancer of the Oropharynx, Oral Cavity, Colon or Liver
Centre Hospitalier Universitaire Dijon306 enrolled1 locationNCT06600295
Recruiting
Not Applicable

Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening

Oropharynx Cancer
The Institute of Molecular and Translational Medicine, Czech Republic20,000 enrolled5 locationsNCT07033091
Recruiting
Phase 2

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Oropharynx
University of Virginia90 enrolled5 locationsNCT05962242
Recruiting
Phase 2

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Oropharyngeal CancerSquamous Cell Carcinoma of the Oropharynx
University of Michigan Rogel Cancer Center150 enrolled1 locationNCT05894083
Recruiting
Not Applicable

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

Head and Neck CancerHead and Neck Squamous Cell CarcinomaOral Cavity Cancer+2 more
Medical University of South Carolina532 enrolled4 locationsNCT05793151
Recruiting
Phase 2

Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma

Oropharynx Cancer
University of Zurich120 enrolled5 locationsNCT06563362
Recruiting
Phase 2

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
University of Maryland, Baltimore61 enrolled5 locationsNCT06088381